NYSE:SLS - Galena Biopharma Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.40 -0.03 (-2.10 %)
(As of 02/17/2019 04:00 PM ET)
Previous Close$1.40
Today's Range$1.40 - $1.43
52-Week Range$0.80 - $11.09
Volume221,549 shs
Average Volume286,103 shs
Market Capitalization$30.84 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Develop biopharmaceuticals

Receive SLS News and Ratings via Email

Sign-up to receive the latest news and ratings for SLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
CUSIPN/A
WebN/A
Phone(917) 438-4353

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$30.84 million
OptionableNot Optionable

Galena Biopharma (NYSE:SLS) Frequently Asked Questions

What is Galena Biopharma's stock symbol?

Galena Biopharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "SLS."

When is Galena Biopharma's next earnings date?

Galena Biopharma is scheduled to release their next quarterly earnings announcement on Friday, April 12th 2019. View Earnings Estimates for Galena Biopharma.

What price target have analysts set for SLS?

1 brokers have issued 12 month price objectives for Galena Biopharma's shares. Their forecasts range from $11.00 to $11.00. On average, they anticipate Galena Biopharma's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 685.7% from the stock's current price. View Analyst Price Targets for Galena Biopharma.

What is the consensus analysts' recommendation for Galena Biopharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galena Biopharma in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Galena Biopharma.

Has Galena Biopharma been receiving favorable news coverage?

Press coverage about SLS stock has trended somewhat positive recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Galena Biopharma earned a news impact score of 1.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term.

Who are some of Galena Biopharma's key competitors?

Who are Galena Biopharma's key executives?

Galena Biopharma's management team includes the folowing people:
  • Angelos M. Stergiou, President, Chief Executive Officer & Director
  • Aleksey N. Krylov, Chief Financial Officer, Treasurer & Director
  • Nicholas J. Sarlis, Director, Chief Medical Officer & Senior VP
  • Barbara A. Wood, Secretary, Executive VP & General Counsel
  • Gregory M. Torre, Director, Chief Regulatory Officer & Senior VP

How do I buy shares of Galena Biopharma?

Shares of SLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Galena Biopharma's stock price today?

One share of SLS stock can currently be purchased for approximately $1.40.

How big of a company is Galena Biopharma?

Galena Biopharma has a market capitalization of $30.84 million.

How can I contact Galena Biopharma?

The company can be reached via phone at (917) 438-4353.


MarketBeat Community Rating for Galena Biopharma (NYSE SLS)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  45 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  96
MarketBeat's community ratings are surveys of what our community members think about Galena Biopharma and other stocks. Vote "Outperform" if you believe SLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SLS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel